Carl Zeiss Meditec Reports Revenue Growth for First Half of 2024/25

Carl Zeiss Meditec AG has reported a revenue increase in the first half of fiscal year 2024/25, reaching €1,050.5 million, a 10.9% growth compared to the prior year. Although EBITA slightly increased to €113.6 million, the margin decreased to 10.8% from 12.0% last year. The growth was driven by a 15.4% revenue rise in the Ophthalmology business unit, boosted by the acquisition of DORC. Microsurgery saw a 1.7% decline in revenue.

The Americas region saw the strongest growth, with a 28.4% increase in revenue, attributed to a recovery in the US market. EMEA and APAC regions also experienced revenue increases of 14.1% and 0.2%, respectively. Despite macroeconomic challenges, including US trade tariffs and currency volatility, the company maintains a stable outlook for the remainder of the year. Earnings per share decreased to €0.70 from €0.94.